louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06380257: Anorexia Nervosa and Brain in Adolescence
Official title: Anorexia Nervosa and Brain in Adolescence
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Anorexia Nervosa
Lead sponsor: Kuopio University Hospital
Sponsor class: OTHER
First posted: 2024-04-23
Enrollment: 50
Sex: ALL
Minimum age (years): 16
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Target study population is 50 participants. Study group (25 participants) are recruited from North Savo wellbeing services, Adolescent psychiatry outpatient clinic. Control group (25 participants) are recruited from Kuopio restrict lower and upper secondary schools.

Brief summary: Aims of this follow-up study are to investigate effects of anorexia nervosa on brain structure and functions in adolescence.

Detailed description: Anorexia nervosa is severe mental health problem with increased incidence rates in adolescence. Etiology of anorexia nervosa is still mostly unkonwn. Adolescence is also critical period of brain development.

Aims of this follow-up study are to investigate effects of anorexia nervosa on brain structure and functions in both acute and remission state of anorexia nervosa in adolescence.

Study group are young anorexia nervosa patients, and control group are healthy same-aged students.

Research methods include non-invasive brain imaging methods such as Transcranial Magnetic Stimulation (TMS), and Magnetic Resonance Imaging (MRI). Other research methods are assessment of body composition, laboratory tests, self-rated questionnaires and psychiatric interview.

Eligibility criteria: Inclusion Criteria:

Study group: 1) age 16-19 years, 2) BMI below 17.5, 3) diagnosis: anorexia nervosa or atypical anorexia nervosa 4) diagnosed within last two years. Inclusion criteria.

Control group : 1) age 16-19 years, 2) BMI over 19.0, 3) No lifetime obesity (BMI over 30) nor eating disorder.

Exclusion Criteria:

1) glucose metabolism disorder or any chronic medical disorder, or medicine with possible effects on neurotransmitters, 2) previous mental health problem (excluded anorexia nervosa or atypical anorexia nervosa in study group), 3) smoking, nicotine products, alcohol or any other substance abuse or dependence, 4) contraindication for used brain imaging method.

Primary outcomes:
measure: Neuroimaging
timeFrame: Baseline and at 3 years' follow-up
Secondary outcomes:
measure: Neuroimaging
timeFrame: Baseline and at 3 years' follow-up
Other outcomes:
measure: Psychiatric evaluation
timeFrame: Baseline and at 3 years' follow-up
measure: Body composition measurement
timeFrame: Baseline and at 3 years' follow-up
measure: Laboratory tests
timeFrame: Baseline and at 3 years' follow-up
Locations:
Study officials:
affiliation: Kuopio University Hospital
name: Virve Kekkonen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02069457: Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis
Official title: Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Cirrhosis
Portal Vein Thrombosis
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2014-02-24
Enrollment: 151
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cirrhosis of any etiology and severity

Brief summary: Several studies have confirmed that patients with cirrhosis possess an imbalance in procoagulant versus anticoagulant activity due to increased factor VIII and decreased protein C. Moreover, in the last two decades there has been an increased recognition that not only bleeding but also thrombosis complicates the clinical course of cirrhosis. The prevalence and pathogenesis of portal vein thrombosis (PVT) in patients with cirrhosis without hepatocellular carcinoma are not clearly defined. The Aim of this study is to assess the prevalence of portal vein thrombosis in patients with cirrhosis without hepatocellular carcinoma, and to prospectively assess the risk factors, outcome, and prognosis in these patients. The investigators plan to enroll two hundred patients with liver cirrhosis. The patients are going to follow up for one year and evaluate at baseline and every 6 months by liver function tests, coagulation test, upper abdomen ultrasound. All relevant clinical events will be evaluated at every follow up.


Eligibility criteria: Inclusion Criteria:

Cirrhosis of any etiology and severity, Aged 18-80 years, Signed Informed Consent.

Exclusion Criteria:

Hepatocellular carcinoma, other intrahepatic/extrahepatic cancers, documented history of congenital coagulation disorders, pregnancy, human immunodeficiency virus (HIV) positivity, recent (\<7 d) transfusion with blood products, use of anticoagulant/antiaggregation drugs in the past 10 d.

Primary outcomes:
measure: Presence of portal vein thrombosis
timeFrame: 6 months
Secondary outcomes:
measure: Cirrhosis Complications
timeFrame: 1 year
measure: Incidence of portal vein thrombosis
timeFrame: 1 year
measure: mortality
timeFrame: 1 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Friendship Hospital
state: Beijing
Study officials:
affiliation: Beijing Friendship Hospital
name: Jidong Jia, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06008457: Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit
Official title: Prospective Clinical Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit as Offered Commercially by Labcorp - A Registry Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19 Respiratory Infection
Influenza A
Influenza Type B
RSV Infection
Lead sponsor: Sequenom, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Labcorp Corporation of America Holdings, Inc
First posted: 2023-08-23
Enrollment: 990
Sex: ALL
Minimum age (years): 2
Maximum age (years): 89
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male or female patients ≥2 years of age who present to the participating study clinics with symptoms of viral respiratory infection consistent with Flu A, Flu B, RSV and/or C-19 and who meet all study inclusion criteria and no exclusion criteria will be considered for enrollment.

Brief summary: To compare the results obtained by analysis of a self-collected anterior nasal (AN) swab as part of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit to a healthcare provider (HCP)-collected AN swab in patients with symptoms of viral respiratory infection consistent with influenza A (Flu A), influenza B (Flu B), respiratory syncytial virus (RSV) and/or SARS-CoV-2 (C-19).


Eligibility criteria: Inclusion Criteria:

* presents with symptoms of viral respiratory infection consistent with Flu A, Flu B, RSV and/or C-19;
* Subject can read and understand written instructions in English; and
* Subject is able, in the professional opinion of the investigator, to provide up to 18.5mL of whole blood at the clinic visit. NOTE - the blood draw will be optional for subjects \<12 years of age.

Exclusion Criteria:

* no personal access to the internet and no email address
* Subject is 14-17 years of age and their parent or legal guardian is unable to supervise the collection of the AN swab sample from the subject;
* Subject is \<14 years of age and their parent or legal guardian refuses to collect the AN swab sample from the subject; or
* Previous participation in this protocol.

Primary outcomes:
measure: Collection method comparison
timeFrame: 1 day
Secondary outcomes:
measure: Whole blood specimen collection
timeFrame: 1 day
Other outcomes:
Locations:
city: Pasadena
country: United States
facility: Exer Urgent Care
state: California
Study officials:
affiliation: Laboratory Corporation of America
name: Graham McLennan, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT00153348: South Central Foundation - WISEWOMAN Project
Official title: South Central Foundation - WISEWOMAN Project
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: CVD Risk
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
First posted: 2005-09-12
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 64
Standard ages: ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To provide low-income, under- or uninsured 40- to 64-year-old women with the knowledge, skills, and opportunities to improve diet, physical activity, and other lifestyle behaviors to prevent, delay and control cardiovascular and other chronic diseases.

Detailed description: To provide low-income, under- or uninsured 40- to 64-year-old women with the knowledge, skills, and opportunities to improve diet, physical activity, and other lifestyle behaviors to prevent, delay and control cardiovascular and other chronic diseases.

Eligibility criteria: Inclusion Criteria:

* NBCCEDP

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Centers for Disease Control and Prevention
name: Julie Will
role: STUDY_CHAIR
References:
Clinical trial NCT01743157: Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
Official title: A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Metastatic Melanoma
Lead sponsor: California Pacific Medical Center Research Institute
Sponsor class: OTHER
First posted: 2012-12-06
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).

Detailed description: A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy (Temodar,Cisplatin, Velban,IL2 and IFN)plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)

Eligibility criteria: Inclusion Criteria:

1. Stage 4 or unresectable stage 3 metastatic melanoma with or without measurable disease
2. Age 18-70 years old
3. Adequate pulmonary and cardiac function for high-dose IL-2
4. PS 0-2
5. Previous ipilimumab therapy will not exclude patients, but patients with previous ipilimumab will have separate efficacy analysis

Exclusion Criteria:

1. Brain metastases
2. Creatinine \> 2x ULN; bilirubin \> 3, WBC \< 3500, Platelets \< 100,000, Hgb \< 9
3. Another active malignancy
4. Gastrointestinal tract metastases except rectal metastases or primary are allowable
5. Previous therapy for metastatic disease with chemotherapy of duration over 3 months or with high-dose interleukin-2
6. History of colitis or autoimmune disease such as lupus or rheumatoid arthritis
7. Bevacizumab-related contraindications: Hemoptysis or history of severe bleeding, uncontrolled hypertension, proteinuria with protein/creatinine ratio \> 1, acute myocardial infarction within 6 months

Primary outcomes:
measure: A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy and Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)
timeFrame: Primary Objective
Secondary outcomes:
measure: A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy and Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)
timeFrame: Secondary Objective
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: San Francisco Oncology Associates
state: California
Study officials:
affiliation: California Pacific Medical Center
name: David R Minor, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: 3. Minor DR, Wang W, Kashani-Sabet: Concurrent bevacizumab (BEV) with biochemotherapy (BIO) followed by ipilimumab for advanced melanoma: a phase I-II trial. J Clin Onc 2013 (suppl; abstr e200001)
Clinical trial NCT00018148: Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Official title: Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Smoking
Keywords: smoking cessation
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2001-07-05
Enrollment: 158
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.


Eligibility criteria: Inclusion Criteria:

* Aged 18-70,
* smoking \> 10 cigarettes per day,
* no current major depression,
* no concurrent psychiatric medications

Exclusion Criteria:

Primary outcomes:
measure: Validated smoking cessation
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: VA Eastern Colorado Health Care System, Denver
state: Colorado
Study officials:
affiliation: VA Eastern Colorado Health Care System, Denver
name: Allan V. Prochazka, MD MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Prochazka AV, Kick S, Steinbrunn C, Miyoshi T, Fryer GE. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med. 2004 Nov 8;164(20):2229-33. doi: 10.1001/archinte.164.20.2229.
Clinical trial NCT00003048: Amifostine in Treating Patients With Myelodysplastic Syndrome
Official title: Phase II Study of Intravenous Amifostine in Myelodysplastic Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Myelodysplastic Syndromes
Keywords: de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
Amifostine
Ethyol
Ethiofos
Gammaphos
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2004-09-06
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome.

PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with myelodysplastic syndrome.

Detailed description: OBJECTIVES: I. Define the activity of amifostine in improving blood counts in patients with myelodysplastic syndrome.

OUTLINE: This is an open label, nonrandomized, single center, dose escalation study. Patients receive amifostine IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks. Responses are evaluated after each cycle (for a minimum of 2 induction cycles). Patients with a grade 0 toxicity in the first course receive a 25% increase in dose during the second course. Patients with grade 1 or 2 toxicity receive no dose change. Patients with grade 3 toxicity receive a 25% reduction in dose or treatment is stopped. All patients demonstrating response are eligible for maintenance therapy. Treatment is continued for up to 12 months or a total of 13 cycles.

PROJECTED ACCRUAL: A total of 14-30 patients will be accrued.

Eligibility criteria: DISEASE CHARACTERISTICS: Histologically proven myelodysplastic syndrome Less than 30% blasts in bone marrow

PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Zubrod 0-2 Karnofsky 60-100% ECOG 0-2 Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 mg/dL Renal: Creatinine no greater than 2 mg/dL Cardiovascular: No New York Heart Association Class IV disease No antihypertensive medication within 24 hours of amifostine administration Other: Not pregnant or nursing Effective contraceptive method must be used during study No medical illness No psychosis Eligible patients with an HLA compatible donor are referred to bone marrow transplantation

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy within 4 weeks of study and recovered Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) of Amifostine
timeFrame: After each 4 week cycle
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: University of Texas - MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Razelle Kurzrock, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02831348: Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases
Official title: Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Allergic Rhinitis
Cystic Fibrosis
Pneumonia
Keywords: Asthma
Allergic rhinitis
Rhinitis
Pneumonia
Cystic fibrosis
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
First posted: 2016-07-13
Enrollment: 59
Sex: ALL
Minimum age (years): 6
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Age range 6-24years old. All genders, races, and ethnicities were sampled, provided they could complete the study requirements.

Brief summary: This is a pilot cross-sectional study of measured transcutaneous CO-oximetry in children with inflammatory and non-inflammatory conditions.

Detailed description: Children and young adults age 6-24 with the following conditions: asthma, pneumonia, allergic rhinitis, cystic fibrosis, and well child (without inflammatory illness) will be recruited.

Subjects will be asked to complete a brief screening survey to determine if they meet inclusion criteria. Enrolled subjects will be asked to complete questionnaire forms to characterize their health, current symptoms, medications, and common exposures. Transcutaneous carboxyhemoglobin will be recorded.

This study is cross-sectional and will only require one visit coinciding with the clinical visit. Analysis will determine the pairwise differences in SpCO between conditions tested.

Eligibility criteria: Inclusion Criteria:

* diagnosis of asthma, pneumonia, allergic rhinitis, or none of the previous (control group)
* Ability to complete study procedures

Exclusion Criteria:

* Cardiopulmonary disease outside of the specific conditions for inclusion
* Prematurity
* Congenital heart disease
* Current diagnosis of more than one of the following: asthma, pneumonia, allergic rhinitis, cystic fibrosis, or - for controls - any current infection
* Recent serious bacterial infection (except for pneumonia in the pneumonia group)
* Concurrent clinical chest X-ray with findings other those that expected for the group (i.e. normal chest X-ray in pneumonia group or suspected pneumonia on chest X-ray in asthma group). To be determined by attending radiologist's interpretation.

Primary outcomes:
measure: SpCO comparison: uncontrolled asthma v. other groups
timeFrame: Time of visit
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Children's Hospital
state: Massachusetts
Study officials:
affiliation: Boston Children's Hospital
name: Jonathan Gaffin, MD. MMSc.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04503148: Anesthesia and Cancer Study: Renal Cell Carcinoma
Official title: The Influence of Type of Anesthesia on Recurrence of Renal Cell Carcinoma After Nephrectomy: a Prospective Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Renal Cell Carcinoma
Keywords: Anesthesia
Propofol
Inhaled anesthetics
Renal cell carcinoma
Nephrectomy
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2020-08-07
Enrollment: 562
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A prospective randomized controlled study
Primary purpose: PREVENTION

Brief summary: This study investigates the influence of type of anesthesia on recurrence and survival of renal cell carcinoma in patients undergoing nephrectomy. The participants will be allocated to either the group receiving the total intravenous anesthesia (TIVA) using propofol or the group receiving the inhaled anesthetics, such as sevoflurane or desflurane.

Detailed description: The effect of anesthesia on cancer recurrence and survival is controversial. According to some retrospective studies and preclinical studies, TIVA is suggested to be more favorable than inhalation anesthesia regarding cancer recurrence and survival after surgery. However, to our knowledge, there is no study which investigates the influence of type of anesthesia on recurrence of renal cell carcinoma after nephrectomy.

Eligibility criteria: Inclusion Criteria:

* Adult patients scheduled for elective nephrectomy due to renal cell carcinoma

Exclusion Criteria:

* Emergency surgery
* Pregnancy
* Allergies to anesthetics
* Palliative surgery
* Refusal to participate in the study
* History of diagnosis or surgery for other cancer

Primary outcomes:
measure: five year metastasis-free survival
timeFrame: five year after surgery
Secondary outcomes:
measure: one year survival
timeFrame: one year after surgery
measure: three year survival
timeFrame: three year after surgery
measure: one year metastasis-free survival
timeFrame: one years after surgery
measure: three year metastasis-free survival
timeFrame: three years after surgery
measure: five year survival
timeFrame: five year after surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References: